Systematic review on treatment cost of multidrug-resistant tuberculosis

J Pharm Pharmacogn Res 6(2): 117-125, 2018.

Review | Revisión

An updated literature review concerning the treatment cost of multidrug-resistant tuberculosis

[Revisión actualizada sobre el costo del tratamiento de la tuberculosis multi-resistente a los fármacos]

Quang Vinh Tran1, Phuong Hong Le1, Nhi Hoang Yen Ngo2, Nam Xuan Vo3, Trung Quang Vo1*

1Department of Pharmacy Administration, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam.
2Faculty of Pharmacy, Nguyen Tat Thanh University, Ho Chi Minh City 700000, Vietnam
3Department of Pharmacy, Division of Social and Administrative Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.

*E-mail: voquangtrungdk@gmail.com

Abstract

Context: According to a report by the World Health Organization (WHO), there were 1.4 million deaths worldwide in 2015 from tuberculosis (TB), with 3.9% being new cases and 21% being previously treated cases of multidrug-resistant tuberculosis (MDR-TB).

Aims: To review the literature concerning the costing analysis situation of MDR-TB treatment.

Methods: The study was conducted as a systematic review, with a modified checklist being used as the vital instrument. A search was performed of three databases (PubMed, Cochrane, and Scopus) using the terms (cost OR economic, socioeconomic, expenditure, burden, fee, charge, budget impact) AND (resistance OR multidrug resistance, MDR) AND (tuberculosis OR TB, Mycobacterium tuberculosis) in order to identify relevant articles published from 2006 to the present.

Results: A total of 1238 abstracts were identified, and 12 papers were ultimately included in the study. The quantity of the published articles was found to increase during in the period 2008 to 2016. Almost all the studies were based on patients’ and healthcare systems’ perceptions. The main data sources used were medical establishments and the reports of various relevant organizations. Primary data were used twice as much as secondary data. All the costing types, including direct costs and indirect costs, were mentioned, albeit not with the same frequency.

Conclusions: Africa owns one-third of the articles included. Further, it was found that MDR-TB should be treated using ambulatory care rather than hospital-based models. Future research studies should focus on Asia, where drug resistance has proved to be a challenging issue.

Keywords: cost; literature review; multi-drug resistant tuberculosis; systematic review; tuberculosis.

Resumen

Contexto: El informe mundial sobre la tuberculosis, presentado por la Organización Mundial de la Salud (OMS) en 2016, muestra que en 2015 hubo 1,4 millones de muertes por tuberculosis, 3,9% de nuevos casos y 21% de casos tratados con tuberculosis multirresistente.

Objetivos: Revisar la literatura científica concerniente al análisis del costo del tratamiento de la tuberculosis multirresistente a fármacos.

Métodos: Este estudio se realizó como una revisión sistemática utilizando una lista de comprobación modificada como un instrumento vital. Una búsqueda en tres bases de datos (PubMed, Cochrane y Scopus) con los términos de (cost OR economic, socioeconomic, expenditure, burden, fee, charge, budget impact) AND (resistance OR multidrug resistance, MDR) AND (tuberculosis OR TB, Mycobacterium tuberculosis) se utilizó para abordar una serie de artículos publicados desde 2006 hasta la actualidad.

Resultados: Se identificaron un total de 1.238 resúmenes y se incluyeron 12 artículos en este estudio. La cantidad de artículos publicados aumentó en el período 2008-2016. La mayoría de los estudios se basaron en la percepción del paciente y del sistema de salud. La fuente de datos utilizada fue principalmente del establecimiento médico y los informes de las organizaciones. Los datos primarios se utilizaron dos veces más que los datos secundarios. Todos los tipos de costos, costos directos e indirectos, fueron mencionados, pero no en la misma frecuencia.

Conclusiones: África posee un tercio de los artículos incluidos. La TB-MDR debe ser tratada con atención ambulatoria en lugar de modelos basados en hospitales. Las investigaciones futuras deberían centrarse en Asia, donde la resistencia a los medicamentos ha sido un tema desafiable.

Palabras Clave: costo; revisión de literatura; revisión sistemática; tuberculosis; tuberculosis multirresistente.

Download the PDF file .

 

Citation Format: Tran QV, Le PH, Ngo NHY, Vo NX, Vo TQ (2018) An updated literature review concerning the treatment cost of multidrug-resistant tuberculosis. J Pharm Pharmacogn Res 6(2): 117–125.

© 2018 Journal of Pharmacy & Pharmacognosy Research (JPPRes)